Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Srinath Muralidharan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
NAR Cancer|July 28, 2021
A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cellsSarthak Sahoo, Ashutosh Mishra, Harsimran Kaur, et al.
Translational Oncology|November 29, 2023
Characterizing heterogeneity along EMT and metabolic axes in colorectal cancer reveals underlying consensus molecular subtype-specific trendsManas Sehgal, Soundharya Ramu, Joel Markus Vaz, et al.
Biomolecules|February 25, 2022
Quantifying the Patterns of Metabolic Plasticity and Heterogeneity along the Epithelial-Hybrid-Mesenchymal Spectrum in CancerSrinath Muralidharan, Sarthak Sahoo, Aryamaan Saha, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
PD-L1 Activity Is Associated with Partial EMT and Metabolic Reprogramming in CarcinomasSrinath Muralidharan, Manas Sehgal, R Soundharya, et al.
Frontiers in Oncology|August 25, 2022
Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axisMaalavika Pillai, Gouri Rajaram, Pradipti Thakur, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
NAR Cancer|July 28, 2021
A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cellsSarthak Sahoo, Ashutosh Mishra, Harsimran Kaur, et al.
Translational Oncology|November 29, 2023
Characterizing heterogeneity along EMT and metabolic axes in colorectal cancer reveals underlying consensus molecular subtype-specific trendsManas Sehgal, Soundharya Ramu, Joel Markus Vaz, et al.
Biomolecules|February 25, 2022
Quantifying the Patterns of Metabolic Plasticity and Heterogeneity along the Epithelial-Hybrid-Mesenchymal Spectrum in CancerSrinath Muralidharan, Sarthak Sahoo, Aryamaan Saha, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
PD-L1 Activity Is Associated with Partial EMT and Metabolic Reprogramming in CarcinomasSrinath Muralidharan, Manas Sehgal, R Soundharya, et al.
Frontiers in Oncology|August 25, 2022
Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axisMaalavika Pillai, Gouri Rajaram, Pradipti Thakur, et al.
Pageof 1